{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:26Z","timestamp":1790716586862,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e38085","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:27:41Z","timestamp":1726738061000},"page":"e38085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?"],"prefix":"10.1016","volume":"10","author":[{"given":"Carlos","family":"Pe\u00f1a-Bates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Lascurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Ortiz-Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2334-0361","authenticated-orcid":false,"given":"Leslie","family":"Chavez-Galan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e38085_bib1","series-title":"Coronavirus Disease (COVID-19): Weekly Epidemiological, Update 1","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e38085_bib2","unstructured":"World Health Organization, Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https:\/\/covid19.who.int\/."},{"issue":"9366","key":"10.1016\/j.heliyon.2024.e38085_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"Coronavirus as a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e38085_bib5","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.cell.2021.08.014","article-title":"Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic","volume":"184","author":"Jackson","year":"2021","journal-title":"Cell"},{"issue":"10229","key":"10.1016\/j.heliyon.2024.e38085_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e38085_bib7","unstructured":"World Health Organization; COVID-19 vaccine tracker and landscape Available from:: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"issue":"10295","key":"10.1016\/j.heliyon.2024.e38085_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomized, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e38085_bib9","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1016\/j.cell.2021.08.014","article-title":"Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic","volume":"184","author":"Jackson","year":"2021","journal-title":"Cell"},{"issue":"30","key":"10.1016\/j.heliyon.2024.e38085_bib10","doi-asserted-by":"crossref","first-page":"17720","DOI":"10.1073\/pnas.2008410117","article-title":"BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)","volume":"117","author":"Escobar","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e38085_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38085_bib12","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/infdis\/jiv332","article-title":"BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study","volume":"212","author":"Leentjens","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12985-020-01402-1","article-title":"Characterization of accessory genes in coronavirus genomes","volume":"17","author":"Michel","year":"2020","journal-title":"Virol. J."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38085_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41422-021-00519-4","article-title":"SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target","volume":"31","author":"Xia","year":"2021","journal-title":"Cell Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38085_bib15","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1128\/JVI.72.8.6838-6850.1998","article-title":"Coronavirus particle assembly: primary structure requirements of the membrane protein","volume":"72","author":"Haan","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib16","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41467-021-23036-9","article-title":"A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation","volume":"12","author":"Kang","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38085_bib17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"J Hoffmann","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.heliyon.2024.e38085_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2021.12.079","article-title":"Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor","volume":"590","author":"Lupala","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e38085_bib19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9366","key":"10.1016\/j.heliyon.2024.e38085_bib20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"Coronavirus is a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.heliyon.2024.e38085_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.heliyon.2024.e38085_bib22","doi-asserted-by":"crossref","DOI":"10.3947\/ic.2024.0024","article-title":"Updated clinical practice guidelines for the diagnosis and management of long COVID","author":"Seo","year":"2024","journal-title":"Infect Chemother"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38085_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41590-021-00937-x","article-title":"TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines","volume":"22","author":"Zheng","year":"2021","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06187","article-title":"SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages","volume":"7","author":"Shirato","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.heliyon.2024.e38085_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijid.2023.11.032","article-title":"Variant rs4986790 of toll-like receptor 4 affects the signaling and induces cell dysfunction in patients with severe COVID-19","volume":"138","author":"Flores-Gonzalez","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/v14050999","article-title":"SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: a novel molecular target for COVID-19 interventions","volume":"14","author":"Plan\u00e8s","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e38085_bib27","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68563","article-title":"SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-\u03baB pathway","volume":"10","author":"Khan","year":"2021","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e38085_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.150542","article-title":"SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7\/8","volume":"6","author":"Salvi","year":"2021","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38085_bib30","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021109622","article-title":"TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection","volume":"41","author":"Van der Sluis","year":"2022","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00259-22","article-title":"CCR2 signaling restricts SARS-CoV-2 infection","volume":"13","author":"Vanderheiden","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.heliyon.2024.e38085_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799558","article-title":"Persistent oxidative stress and inflammasome activation in CD14highCD16- monocytes from COVID-19 patients","volume":"12","author":"Lage","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-04133-7","article-title":"Modulation of the NLRP3 inflammasome by sars-CoV-2 envelope protein","volume":"11","author":"Yalcinkaya","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib34","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-021-25015-6","article-title":"SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e38085_bib35","doi-asserted-by":"crossref","first-page":"8423","DOI":"10.3390\/ijms22168423","article-title":"Severe COVID-19 patients show an increase in soluble TNFR1 and ADAM17, with a relationship to mortality","volume":"22","author":"Palacios","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e38085_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2023.105179","article-title":"COVID-19 patients with high TNF\/IFN-\u03b3 levels show hallmarks of PANoptosis, an inflammatory cell death","author":"Palacios","year":"2023","journal-title":"Microbes Infect"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/infdis\/jiac101","article-title":"TNFRSF1B and TNF variants are associated with differences in levels of soluble tumor necrosis factor receptors in patients with severe COVID-19","volume":"226","author":"Fricke-Galindo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e38085_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.949413","article-title":"IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19","volume":"13","author":"Fricke-Galindo","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38085_bib39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41418-022-00936-x","article-title":"T cell apoptosis characterizes severe Covid-19 disease","volume":"29","author":"Andr\u00e9","year":"2022","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-020-00334-0","article-title":"SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/JLB.4HI0720-470R","article-title":"COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes","volume":"109","author":"Zhang","year":"2021","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1134\/S1607672922060084","article-title":"Differences in presentation of SARS-CoV-2 omicron strain variant BA.1-BA.5 peptides by HLA molecules","volume":"507","author":"Nersisyan","year":"2022","journal-title":"Dokl. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e38085_bib44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38085_bib45","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1002\/jmv.27917","article-title":"Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients","volume":"94","author":"Idiz","year":"2022","journal-title":"J. Med. Virol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38085_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100685","article-title":"Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine","volume":"3","author":"Weskamm","year":"2022","journal-title":"Cell Reports Med"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib47","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion, and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"De Biasi","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.immuni.2022.01.015","article-title":"Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia","volume":"55","author":"Kreutmair","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e38085_bib49","unstructured":"World Health Organization; COVID-19 vaccine tracker and landscape Available from:: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"10.1016\/j.heliyon.2024.e38085_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1062067","article-title":"Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated","volume":"13","author":"Maaske","year":"2023","journal-title":"Front. Immunol."},{"issue":"29","key":"10.1016\/j.heliyon.2024.e38085_bib51","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1016\/j.vaccine.2023.05.015","article-title":"One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): final analysis of a randomized, placebo-controlled phase 1\/2 trial in Japan","volume":"41","author":"Ishikawa","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38085_bib52","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1016\/S2666-5247(23)00177-5","volume":"4","author":"Ramasamy","year":"2023","journal-title":"Lancet Microbe"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38085_bib53","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa2116747","article-title":"Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming","volume":"386","author":"Sablerolles","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38085_bib54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10255","key":"10.1016\/j.heliyon.2024.e38085_bib55","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.heliyon.2024.e38085_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011211","article-title":"Long term immune response produced by the SputnikV vaccine. Long term immune response produced by the SputnikV vaccine","volume":"22","author":"Martynova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38085_bib57","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1473-3099(23)00295-5","article-title":"Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial","volume":"23","author":"Lee","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38085_bib58","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e38085_bib59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jclinepi.2021.10.011","article-title":"BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals","volume":"142","author":"Mor","year":"2022","journal-title":"J. Clin. Epidemiol."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e38085_bib60","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38085_bib61","unstructured":"Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19. Available from: https:\/\/www.who.int\/publications\/i\/item\/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38085_bib63","article-title":"Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study","author":"Palacios","year":"2021","journal-title":"SSRN Journal"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38085_bib64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38085_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.621","article-title":"Persistence of immune responses to the Sinopharm\/BBIBP-CorV vaccine","volume":"10","author":"Jeewandara","year":"2022","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.heliyon.2024.e38085_bib67","unstructured":"Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP."},{"issue":"6549","key":"10.1016\/j.heliyon.2024.e38085_bib68","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Crotty","year":"2021","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e38085_bib69","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e38085_bib70","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41590-022-01184-4","article-title":"SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells","volume":"23","author":"Minervina","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12864-022-08826-9","article-title":"Genomic characteristics of two most widely used BCG vaccine strains: Danish 1331 and Pasteur 1173P2","volume":"23","author":"Asadian","year":"2022","journal-title":"BMC Genom."},{"key":"10.1016\/j.heliyon.2024.e38085_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/9781555817381.ch30","article-title":"Book section. Mycobacterium: general characteristics, laboratory detection, and staining procedures","author":"Pfyffer","year":"2015","journal-title":"Manual of Clinical Microbiology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38085_bib73","doi-asserted-by":"crossref","DOI":"10.1099\/mic.0.001054","article-title":"Conserved and specialized functions of Type VII secretion systems in non-tuberculous mycobacteria","volume":"167","author":"Lagune","year":"2021","journal-title":"Microbiology (Reading, England)"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e38085_bib74","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1073\/pnas.2235593100","article-title":"Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system","volume":"100","author":"Stanley","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e38085_bib75","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib76","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0378-1135(99)00011-5","article-title":"Intracellular survival of virulent Mycobacterium bovis and M. bovis BCG in ferret macrophages","volume":"66","author":"Cross","year":"1999","journal-title":"Vet. Microbiol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib77","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1189\/jlb.0103026","article-title":"TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG","volume":"74","author":"Heldwein","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1189\/jlb.0105037","article-title":"Mycobacterium bovis bacillus Calmette-Guerin infects DC-SIGN- dendritic cells and causes the inhibition of IL-12 and the enhancement of IL-10 pro-duction","volume":"78","author":"Gagliardi","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e38085_bib79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","article-title":"BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis","volume":"172","author":"Kaufmann","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00496-19","article-title":"Construction and characterization of the Mycobacterium tuberculosis sigE fadD26 unmarked double mutant as a vaccine candidate","volume":"88","author":"Hernandez-Pando","year":"2019","journal-title":"Infect. Immun."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e38085_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109208","article-title":"The impact of BCG dose and revaccination on trained immunity","volume":"246","author":"Debisarun","year":"2023","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38085_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041756","article-title":"Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes","volume":"7","author":"Faustman","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/01.wnl.0000438216.93319.ab","article-title":"Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS","volume":"82","author":"Ristori","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2024.e38085_bib85","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.3389\/fimmu.2018.02777","article-title":"Extended freeze-dried BCG instructed pDCs induce suppressive Tregs and dampen EAE","volume":"9","author":"Lippens","year":"2018","journal-title":"Front. Immunol."},{"issue":"17\u201318","key":"10.1016\/j.heliyon.2024.e38085_bib86","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.vaccine.2005.01.015","article-title":"Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits","volume":"23","author":"Uyl-de Groot","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e38085_bib87","first-page":"225","article-title":"Treatment of malignant melanoma by intratumoral injection of BCG","volume":"39","author":"Pinsky","year":"1973","journal-title":"Natl. Cancer Inst. Monogr."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38085_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004133","article-title":"BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma","volume":"10","author":"Kremenovic","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38085_bib89","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib90","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41590-023-01739-z","article-title":"BCG immunization induces CX3CR1hi effector memory T cells to provide cross-protection via IFN-\u03b3-mediated trained immunity","volume":"25","author":"Tran","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","article-title":"BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity","volume":"23","author":"Arts","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2024.e38085_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100517","article-title":"Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial","volume":"27","author":"Abarca","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38085_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180143","article-title":"Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia","volume":"12","author":"Mukherjee","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38085_bib94","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157393","article-title":"Bacillus Calmette-Gu\u00e9rin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e38085_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110502","article-title":"BCG vaccination provides protection against IAV but not SARS-CoV-2","volume":"38","author":"Kaufmann","year":"2022","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib96","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.imj.2023.08.004","article-title":"Bacille-Calmette-Guerin modulates human macrophage and dendritic cell response to SARS-CoV-2 S-glycoprotein","volume":"2","author":"Ambe","year":"2023","journal-title":"Infect. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38085_bib97","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"O'Neill","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"41","key":"10.1016\/j.heliyon.2024.e38085_bib98","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1016\/j.vaccine.2020.08.045","article-title":"BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis","volume":"38","author":"Tomita","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e38085_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799896","article-title":"Mitochondrial dysfunction associates with acute T lymphocytopenia and impaired functionality in COVID-19 patients","volume":"12","author":"Mo","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e38085_bib100","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.4049\/jimmunol.2100068","article-title":"Metabolic defects of peripheral T cells in COVID-19 patients","volume":"206","author":"Liu","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/aps.2008.3","article-title":"Neonatal bacillus Calmette-Gu\u00e9rin vaccination inhibits de novo allergic inflammatory response in mice via alteration of CD4+CD25+ T-regulatory cells","volume":"30","author":"Li","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2024.e38085_bib102","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3389\/fimmu.2018.00583","article-title":"The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells","volume":"9","author":"Ye","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib103","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells","volume":"179","author":"Chen","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib104","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jinf.2021.07.029","article-title":"Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection","volume":"83","author":"Rajamanickam","year":"2021","journal-title":"J. Infect."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e38085_bib105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/resp.13885","article-title":"National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19","volume":"25","author":"Ebina-Shibuya","year":"2020","journal-title":"Respirology"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e38085_bib106","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.3390\/ijerph17155589","article-title":"BCG vaccination and mortality of COVID-19 across 173 countries: an ecological study","volume":"17","author":"Urashima","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38085_bib107","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jinf.2020.08.013","article-title":"Impact of routine infant BCG vaccination on COVID-19","volume":"81","author":"Kinoshita","year":"2020","journal-title":"J. Infect."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib108","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/vaccines8030378","article-title":"Significantly improved COVID-19 outcomes in countries with higher BCG vaccination coverage: a multivariable analysis","volume":"8","author":"Klinger","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e38085_bib109","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/all.14345","article-title":"Is global BCG vaccination-induced trained immunity relevant to the progression of the SARS-CoV-2 pandemic?","volume":"75","author":"Gursel","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.heliyon.2024.e38085_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101414","article-title":"Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: a double-blind, randomized, controlled, phase 3 trial","volume":"48","author":"Upton","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38085_bib111","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.cmi.2022.04.009","article-title":"Bacillus Calmette-Gu\u00e9rin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial","volume":"28","author":"Ten Doesschate","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e38085_bib112","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMoa2212616","article-title":"Randomized trial of BCG vaccine to protect against covid-19 in health care workers","volume":"388","author":"Pittet","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib113","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00356-23","article-title":"CG vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial","volume":"14","author":"Claus","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.heliyon.2024.e38085_bib114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijid.2023.02.014","article-title":"The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil","volume":"130","author":"Santos","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e38085_bib115","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.cmi.2023.01.019","article-title":"Bacillus Calmette-Gu\u00e9rin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial","volume":"29","author":"Koekenbier","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e38085_bib116","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/cid\/ciac182","article-title":"Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic","volume":"75","author":"Moorlag","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e38085_bib117","article-title":"ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk","volume":"13","author":"Tsilika","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e38085_bib118","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/vaccines12030242","article-title":"Host genetic background influences BCG-induced antibodies cross-reactive to SARS-CoV-2 spike protein","volume":"12","author":"Specht","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib119","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211862","article-title":"Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge","volume":"219","author":"Hilligan","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e38085_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801799","article-title":"Influence of aerosol delivered BCG vaccination on immunological and disease parameters following SARS-CoV-2 challenge in rhesus macaques","volume":"12","author":"White","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e38085_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/srep15443","article-title":"Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations","volume":"5","author":"Abdallah","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e38085_bib122","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/mt.2015.216","article-title":"Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e38085_bib123","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.3390\/cells10113179","article-title":"Effect of BCG revaccination on occupationally exposed medical personnel vaccinated against SARS-CoV-2","volume":"10","author":"Ramos-Martinez","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.heliyon.2024.e38085_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.985938","article-title":"Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD\u2122 vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults","volume":"13","author":"Rakshit","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e38085_bib125","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/joim.13523","article-title":"Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: clinical evolution, adverse events, and humoral immune response","volume":"292","author":"Jalalizadeh","year":"2022","journal-title":"J. Intern. Med."},{"issue":"32","key":"10.1016\/j.heliyon.2024.e38085_bib126","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1016\/j.vaccine.2022.06.039","article-title":"BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial","volume":"40","author":"Dionato","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e38085_bib127","unstructured":"ClinicalTrials.gov. [ID: NCT02403505]. Available from: https:\/\/classic.clinicaltrials.gov\/ProvidedDocs\/05\/NCT02403505\/ICF_003.pdf."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e38085_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107612","article-title":"BCG administration promotes the long-term protection afforded by a single-dose intranasal adenovirus-based SARS-CoV-2 vaccine","volume":"26","author":"Perera","year":"2023","journal-title":"iScience"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024141163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024141163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:36:09Z","timestamp":1790714169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024141163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":127,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024141163"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38085","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38085"}}